(NASDAQ: MTSR) Metsera's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 52.93%.
Metsera's earnings in 2025 is N/A.On average, 2 Wall Street analysts forecast MTSR's earnings for 2025 to be -$348,784,386, with the lowest MTSR earnings forecast at -$362,441,606, and the highest MTSR earnings forecast at -$335,127,166.
In 2026, MTSR is forecast to generate -$369,270,216 in earnings, with the lowest earnings forecast at -$381,351,603 and the highest earnings forecast at -$357,188,829.